Want to see TSE:LOVE full AI Analyst Report?
LOVE Stock Chart & Stats
C$1.99
-C$0.04(-2.11%)
At close: 4:00 PM EDT
C$1.99
-C$0.04(-2.11%)
Day’s Range― - ―
52-Week RangeC$1.55 - C$2.37
Previous CloseN/A
Volume10.70K
Average Volume (3M)41.26K
Market Cap
C$218.31M
Enterprise ValueC$183.06
Total Cash (Recent Filing)C$21.81M
Total Debt (Recent Filing)C$37.00M
Price to Earnings (P/E)19.5
Beta0.34
Next Earnings
Nov 24, 2026EPS Estimate
0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.11
Shares Outstanding98,782,150
10 Day Avg. Volume66,076
30 Day Avg. Volume41,261
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)1.63
Price to Sales (P/S)1.55
P/FCF Ratio12.18
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$3.33Price Target Upside67.50% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)0.2
Revenue Forecast (FY)C$138.99M
Bulls Say, Bears Say
Bulls Say
Revenue And Market Share GrowthDouble-digit revenue growth alongside expanding national market share indicates stronger product demand and distribution effectiveness. Sustained retail penetration can improve brand visibility, support greater facility utilization, and provide a durable foundation for revenue growth over the next several quarters.
Consistent Profitability And Cash GenerationA long record of positive adjusted EBITDA and operating cash flow demonstrates that Cannara has moved beyond early-stage losses into repeatable operating profitability. This supports internally funded expansion, improves resilience, and gives management more flexibility in allocating capital.
Accelerated Production CapacityExpanding cultivation capacity ahead of the prior timetable positions Cannara to serve rising demand and capture more provincial distribution opportunities. The existing footprint provides additional long-term operating leverage if the company can fill new rooms and maintain product quality and margins.
Bears Say
Margin CompressionThe sharp reduction in gross margin and weaker operating profitability shows that recent revenue growth is not translating consistently into earnings. If product mix or cost pressures persist, lower margins could limit reinvestment capacity and reduce the benefit of expanding production volume.
Volatile Free Cash FlowFree cash flow volatility makes it harder to determine how much expansion can be funded internally without increased borrowing. The recent decline indicates that capital spending or working-capital needs are absorbing a larger share of operating cash, potentially constraining flexibility during the buildout.
Competitive Category PressureGreater competition for shelf space and pressure in live resin vapes can raise customer-acquisition costs while limiting pricing power. Cannara may need sustained marketing investment or targeted price adjustments to protect volume, which could weigh on category profitability and brand economics.
LOVE FAQ
What was Cannara Biotech’s price range in the past 12 months?
Cannara Biotech lowest stock price was C$1.55 and its highest was C$2.37 in the past 12 months.
What is Cannara Biotech’s market cap?
Cannara Biotech’s market cap is C$218.31M.
When is Cannara Biotech’s upcoming earnings report date?
Cannara Biotech’s upcoming earnings report date is Nov 24, 2026 which is in 58 days.
How were Cannara Biotech’s earnings last quarter?
Cannara Biotech released its earnings results on Jul 15, 2026. The company reported C$0.05 earnings per share for the quarter.
Is Cannara Biotech overvalued?
According to Wall Street analysts Cannara Biotech’s price is currently Undervalued.
Does Cannara Biotech pay dividends?
Cannara Biotech does not currently pay dividends.
What is Cannara Biotech’s EPS estimate?
Cannara Biotech’s EPS estimate is 0.04.
How many shares outstanding does Cannara Biotech have?
Cannara Biotech has 98,782,150 shares outstanding.
What happened to Cannara Biotech’s price movement after its last earnings report?
Cannara Biotech reported an EPS of C$0.05 in its last earnings report. Following the earnings report the stock price went down -1.053%.
Which hedge fund is a major shareholder of Cannara Biotech?
Currently, no hedge funds are holding shares in TSE:LOVE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cannara Biotech
Cannara Biotech Inc., alongside its affiliated entities, specializes in the indoor cultivation, processing, and distribution of cannabis and related products across Canada. The company operates with a dual business model, encompassing both cannabis operations and real estate activities. Its diverse product portfolio is marketed under distinct brand names such as TRIBAL, nugz, and ORCHID CBD. Distribution is managed through both wholesale channels and online retail platforms. Established in 2017, Cannara Biotech Inc. maintains its headquarters in Saint-Laurent, Canada.
LOVE Company Deck
LOVE Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a broadly positive operational and financial picture: double-digit revenue growth (16% QoQ), continued profitability (adjusted EBITDA up 11% and 21 consecutive positive quarters), strengthened market penetration (national share gains and record monthly shares in Ontario and Alberta), accelerated capacity expansion and strategic partnerships (Medican acquisition, Blue River technology, CAD 21M Curaleaf agreement). Notable near-term negatives include lower quarterly free cash flow and operating cash flow versus the prior year driven by higher expansion capex, a modest dip in gross margin from product mix, higher receivables and inventory, and competitive pressures in certain categories. On balance, the highlights — consistent profitability, expanding distribution and market share, accelerated capacity rollout, and strategic deals — outweigh the lowlights tied to timing, investment-driven cash flow effects, and category competition.View all TSE:LOVE earnings summariesLOVE Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
C$3.33
▲(67.50% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month
Jushi Holdings
―
Organigram Global
―
Auxly Cannabis Group
―
―
Grown Rogue International
―










